Harnessing the power of regenerative medicine to regenerate, repair and restore
At Sarcio Inc., we believe in innovation with purpose. Founded on the principles of integrity, collaboration, and forward-thinking, Sarcio is committed to delivering solutions that not only meet today’s needs but also anticipate tomorrow’s challenges. Our multidisciplinary team brings deep expertise, creativity, and a relentless drive for excellence in everything we undertake.
Sarcio Inc. emerged as a pioneering spin-out from the University of Minnesota's Stem Cell Institute (SCI), the nation's first interdisciplinary institute dedicated exclusively to stem cell research. The company's foundational technology was developed in the laboratory of Dr. Timothy O'Brien, a professor and division head of comparative pathology at the University of Minnesota.
Recognizing the potential to address the challenges of osteoarthritis, the team focused on isolating exosomes from induced pluripotent stem cells (iPSCs) derived cartilage tissue as novel regenerative disease-modifying therapeutics to restore joint function and delay or eliminate the need for joint-replacement surgery.
Our Team
Beth Lindborg, MS, MBA
Founder & Chief Executive Officer, Director
Beth is a successful entrepreneur with over $8 million raised across ventures, and a proven track record in both startups and established life science companies. She has held senior roles spanning commercial strategy, marketing, and operations. Recognized as a “Notable Women Entrepreneur,” Beth brings a rare blend of strategic vision and executional excellence to every endeavor.
Timothy D. O’Brien, DVM, PhD, DACVP
Founder & Chief Scientific Officer, Director
Tim O’Brien is a board-certified veterinary pathologist with 35 years of experience in biomedical research at the University of Minnesota, where he is a professor and division head of comparative pathology in the Department of Veterinary Population Medicine. He has held leadership roles at the University of Minnesota Stem Cell Institute, where his laboratory developed novel stem-cell technologies.
Amanda Vegoe, BS
Founder & Chief Operations Officer
Amanda has more than 20 years of experience in project management, molecular biology, and regenerative medicine innovation. She joined the O’Brien Lab in 2013, where she worked on the development of multi-tissue organoids and the scale-up of high-quality human cartilage cells.
Marc Tompkins, MD
Chief Medical Officer
Marc brings extensive clinical expertise in joint preservation, orthopedic surgery, and regenerative medicine. He is widely published in leading orthopedic journals and remains actively involved in national and international orthopedic organizations. Throughout his career, Marc has participated in numerous clinical trials, reflecting his deep commitment to advancing the field through evidence-based innovation.
Michael Williams
Chief Business Officer
Michael brings over 30 years of global leadership in the biopharmaceutical industry, with senior roles at BMS, Pfizer, and Takeda. He has launched multiple blockbuster drugs and played a pivotal role in supporting companies that have raised over $300 million.